我們報告一位65歲的直腸癌合併肝臟轉移的患者來署立台南醫院接受治療，前後一共歷經三次切肝手術和多次化學治療，並探討此類患者治療之最新進展。Neoadjuvant 化學治療可用FOLFOX 或者 FOLFIRI，亦可考慮合併標靶藥物如 bevacizumab 或是 cetuximab。術後化學治療有可能是必要的，但仍需更多證據來支持，其他如肝動脈注射化療仍在實驗階段。而正子攝影的檢查目前是建議使用在有開刀可能性的患者身上。

We report a 65-year-old male with rectal cancer who received three hepatic operations and chemotherapy at Tainan Hospital, and the recent advances in hepatic colorectal metastases are also reviewed. Neoadjuvant chemotherapy includes FOLFOX or FOLFIRI with either bevacizumab or
cetuximab. There may be a role for adjuvant chemotherapy, but further study is needed. Other options,such as hepatic arterial infusion, have been studied in clinical trials. Preoperative PET/CT is indicated only
in the presence of potentially surgically curable M1 disease.